A 72-year-old man with non-valvular atrial fibrillation and CHA₂DS₂-VASc score of 3 (age, hypertension, diabetes) has normal renal function and no history of major bleeding. According to Australian practice, what is the most appropriate antithrombotic strategy to reduce his stroke risk?